R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphomaOACSCDCSTPCD
R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma
To further explore the role of rituximab when added to the CHOP-like regimen in the treatment of immunohistochemically defined non-germinal center B-cell subtype (non-GCB) diffuse large B-cell lymphoma (DLBCL),159 newly diagnosed DLBCL patients were studied retrospectively based on the immunohistochemical evaluation of CD10,Bcl-6,MUM-1,and Bcl-2.Altogether,110 patients underwent the CHOP-like regimen,and rituximab was added for the other 49 patients.Cox reg…查看全部>>
Xiao-Hui He;Mei Dong;Sheng-Yu Zhou;Jian-Liang Yang;Peng Liu;Chang-Gong Zhang;Yan Qin;Feng-Yi Feng;Yuan-Kai Shi;Bo Li;Sheng Yang;Ning Lu;Xun Zhang;Shuang-Mei Zou;Ye-Xiong Li;Yong-Wen Song;Shan Zheng
Department of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Pathology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Pathology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Pathology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. ChinaDepartment of Pathology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. China
Diffuse large B-cell lymphomarituximabchemotherapyNF-κBimmunohistochemistry
Diffuse large B-cell lymphomarituximabchemotherapyNF-κBimmunohistochemistry
《癌症（英文版）》 2012 (6)
306-314,9
评论